Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ.
Wiseman GA, et al. Among authors: spies s.
Eur J Nucl Med. 2000 Jul;27(7):766-77. doi: 10.1007/s002590000276.
Eur J Nucl Med. 2000.
PMID: 10952488
Clinical Trial.